Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: A study of 42 patients

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1691-1697

  Boussemart, L ^a,b   Routier, E ^a   Mateus, C ^a   Opletalova, K ^a   Sebille, G ^a   Kamsu Kom, N ^b   Thomas, M ^a   Vagner, S ^b   Favre, M ^c   Tomasic, G ^a   Wechsler, J ^a   Lacroix, L ^b   Robert, C ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

BRAF inhibitor; Mmelanoma; Side effects; Squamous cell carcinoma targeted therapy; Vemurafenib

Indexed keywords

VEMURAFENIB;

ADULT; AGED; ALOPECIA; ARTICLE; CHEILITIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG ERUPTION; EPIDERMOID CYST; FACE ERYTHEMA; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; KERATOACANTHOMA; MALE; METASTATIC MELANOMA; NEVUS; OVERALL SURVIVAL; PANNICULITIS; PHOTOGRAPHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SKIN BIOPSY; SKIN CANCER; SKIN CYST; SKIN DISEASE; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; SYMPTOMATOLOGY; VERRUCOUS CARCINOMA; XEROSIS;

EID: 84878451069     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt015     Document Type: Article

References (21)

1. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-954.
2. Arnault JP, Wechsler J, Escudier B et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27(23): e59-e61.
3. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507-2516.
4. Hong S, Hong S, Han SB. Overcoming metastatic melanoma with BRAF inhibitors. Arch Pharm Res 2011; 34(5): 699-701.
5. Kong HH, Sibaud V, Chanco Turner ML et al. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 2008; 144(6): 820-822.
6. Tsoumpou I, Arbyn M, Kyrgiou M et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009; 35(3): 210-220.
7. Autier J, Escudier B, Wechsler J et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144(7): 886-892.
8. Szigeti R, Kellermayer R. Autosomal-dominant calcium ATPase disorders. J Invest Dermatol 2006; 126(11): 2370-2376.
9. Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464(7287): 431-435.
10. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366(3): 207-215.
11. Blank C, Del Vecchio M, Ascierto PA et al. Personal communication, ESMO 2012.
12. Arnault JP, Mateus C, Escudier B et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 2012; 18(1): 263-272.
13. Zimmer L, Hillen U, Livingstone E et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30(19): 2375-2383.
14. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 365(15): 1448-1449.
15. Oberholzer PA, Kee D, Dziunycz P et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30(3): 316-321.
16. Saltz LB, Meropol NJ, Loehrer PJ, Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor [abstract]. J Clin Oncol 2004; 22: 1201-1208.
17. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
18. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012; 366(5): 480-481.
19. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380(9839): 358-365.
20. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367(2): 107-114.
21. Falchook GS, Lewis KD, Infante JR et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13(8): 782-789.